{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T05:39:10Z","timestamp":1698730750187},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40121-016-0116-z","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T06:02:34Z","timestamp":1467871354000},"page":"313-327","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hepatitis C Therapy in Renal Patients: Who, How, When?"],"prefix":"10.1007","volume":"5","author":[{"given":"Corinne","family":"Isnard Bagnis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"116_CR1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359\u201362.","journal-title":"Science"},{"issue":"10","key":"116_CR2","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","volume":"42","author":"P Cacoub","year":"1999","unstructured":"Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum. 1999;42(10):2204\u201312.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 5","key":"116_CR3","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","volume":"46","author":"P Cacoub","year":"2014","unstructured":"Cacoub P, Gragnani L, Commarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46 Suppl 5:S165\u201373.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"116_CR4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","volume":"17","author":"D Lavanchy","year":"2011","unstructured":"Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107\u201315.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"116_CR5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","volume":"65","author":"RB Fissell","year":"2004","unstructured":"Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335\u201342.","journal-title":"Kidney Int"},{"key":"116_CR6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","volume":"38","author":"DA Goodkin","year":"2013","unstructured":"Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38:405\u201312.","journal-title":"Am J Nephrol"},{"key":"116_CR7","doi-asserted-by":"crossref","unstructured":"Isnard Bagnis C, Layese R, Divard G, et al and ANRS CO12 CirVir prospective group. Viral suppression is not a risk factor for CKD in viral cirrhosis (ANRS CO12 CIRVIR Prospective cohort). Poster and e poster EASL 2016, Barcelona, ILC2016-RS-1182.","DOI":"10.1016\/j.nephro.2016.07.245"},{"issue":"12","key":"116_CR8","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1097\/TP.0000000000000847","volume":"99","author":"D Sawinski","year":"2015","unstructured":"Sawinski D, Bloom RD. Novel hepatitis C treatment and the impact on kidney transplantation. Transplantation. 2015;99(12):2458\u201366. doi: 10.1097\/TP.0000000000000847 .","journal-title":"Transplantation"},{"issue":"9","key":"116_CR9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","volume":"128","author":"P Cacoub","year":"2015","unstructured":"Cacoub P, Comarmond C, Domont C, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med. 2015;128(9):950\u20135.","journal-title":"Am J Med"},{"issue":"4","key":"116_CR10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clinre.2013.02.002","volume":"37","author":"B Terrier","year":"2013","unstructured":"Terrier B, Cacoub P. Renal involvement in HCV-related vasculitis. Clin Res Hepatol Gastroenterol. 2013;37(4):334\u20139.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"116_CR11","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/art.30319","volume":"63","author":"B Terrier","year":"2011","unstructured":"Terrier B, Semoun O, Saadoun D, S\u00e8ne D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63(6):1748\u201357.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"116_CR12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","volume":"33","author":"C Ferri","year":"2004","unstructured":"Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355\u201374.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"116_CR13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2006.08.005","volume":"36","author":"M Ramos-Casals","year":"2006","unstructured":"Ramos-Casals M, Robles A, Brito-Zer\u00f3n P, et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum. 2006;36(3):189\u201396.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"116_CR14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/MD.0b013e3182a5cf71","volume":"92","author":"S Retamozo","year":"2013","unstructured":"Retamozo S, D\u00edaz-Lagares C, Bosch X, et al. Life-threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine (Baltimore). 2013;92(5):273\u2013284.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"116_CR15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.amjcard.2012.09.028","volume":"111","author":"B Terrier","year":"2013","unstructured":"Terrier B, Karras A, Cluzel P, et al. Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis. Am J Cardiol. 2013;111(2):265\u201372.","journal-title":"Am J Cardiol"},{"issue":"9","key":"116_CR16","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/art.21270","volume":"52","author":"D Saadoun","year":"2005","unstructured":"Saadoun D, Bieche I, Maisonobe T, et al. Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum. 2005;52(9):2917\u201325.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"116_CR17","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2003-07-2598","volume":"103","author":"O Boyer","year":"2004","unstructured":"Boyer O, Saadoun D, Abriol J, et al. CD4+ CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood. 2004;103(9):3428\u201330.","journal-title":"Blood"},{"issue":"22","key":"116_CR18","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067\u201377.","journal-title":"N Engl J Med"},{"issue":"9","key":"116_CR19","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/1529-0131(200109)44:9<2118::AID-ART364>3.0.CO;2-X","volume":"44","author":"P Cacoub","year":"2001","unstructured":"Cacoub P, Renou C, Kerr G, et al. Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum. 2001;44(9):2118\u201324.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"116_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/gene.2014.41","volume":"15","author":"AL Zignego","year":"2014","unstructured":"Zignego AL, Wojcik GL, Cacoub P, et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun. 2014;15(7):500\u20135. doi: 10.1038\/gene.2014.41 .","journal-title":"Genes Immun"},{"issue":"5","key":"116_CR21","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/art.30274","volume":"63","author":"L Gragnani","year":"2011","unstructured":"Gragnani L, Piluso A, Giannini C, et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc\u03b3 receptors. Arthritis Rheum. 2011;63(5):1446\u201351.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"116_CR22","doi-asserted-by":"crossref","first-page":"e62965","DOI":"10.1371\/journal.pone.0062965","volume":"8","author":"E Fognani","year":"2013","unstructured":"Fognani E, Giannini C, Piluso A, et al. Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. PLoS One. 2013;8(5):e62965.","journal-title":"PLoS One"},{"issue":"1","key":"116_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2002.34613","volume":"36","author":"F Fabrizi","year":"2002","unstructured":"Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36(1):3\u201310.","journal-title":"Hepatology"},{"issue":"12","key":"116_CR24","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/00007890-199506270-00006","volume":"59","author":"D Roth","year":"1995","unstructured":"Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation. 1995;59(12):1676\u201382.","journal-title":"Transplantation"},{"issue":"6","key":"116_CR25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/hep.1840360621","volume":"36","author":"HB El-Serag","year":"2002","unstructured":"El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36(6):1439\u201345.","journal-title":"Hepatology"},{"issue":"4","key":"116_CR26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2215\/CJN.00470107","volume":"2","author":"LS Dalrymple","year":"2007","unstructured":"Dalrymple LS, Koepsell T, Sampson J, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2(4):715\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"116_CR27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cgh.2009.08.031","volume":"8","author":"SK Asrani","year":"2010","unstructured":"Asrani SK, Buchanan P, Pinsky B, Rey LR, Schnitzler M, Kanwal F. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol. 2010;8(1):79\u201384.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"116_CR28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ajkd.2010.09.023","volume":"57","author":"AA Butt","year":"2011","unstructured":"Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57(3):396\u2013402.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"116_CR29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2010.01.015","volume":"56","author":"J-J Lee","year":"2010","unstructured":"Lee J-J, Lin M-Y, Yang Y-H, Lu S-N, Chen H-C, Hwang S-J. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010;56(1):23\u201331.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"116_CR30","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1681\/ASN.2005091006","volume":"17","author":"JI Tsui","year":"2006","unstructured":"Tsui JI, Vittinghoff E, Shlipak MG, O\u2019Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17(4):1168\u201374.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"116_CR31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1523-1755.2005.00080.x","volume":"67","author":"S Liangpunsakul","year":"2005","unstructured":"Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67(1):285\u201390.","journal-title":"Kidney Int"},{"issue":"4","key":"116_CR32","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","volume":"59","author":"Y-C Hsu","year":"2014","unstructured":"Hsu Y-C, Lin J-T, Ho HJ, Kao Y-H, Huang Y-T, Hsiao N-W, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatol Baltim Md. 2014;59(4):1293\u2013302.","journal-title":"Hepatol Baltim Md."},{"issue":"3","key":"116_CR33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/lt.500010306","volume":"1","author":"CL Davis","year":"1995","unstructured":"Davis CL, Gretch DR, Perkins JD, et al. Hepatitis C-associated glomerular disease in liver transplant recipients. Liver Transpl Surg. 1995;1(3):166\u201375.","journal-title":"Liver Transpl Surg"},{"issue":"12","key":"116_CR34","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1097\/00007890-200212270-00021","volume":"74","author":"T Sikaneta","year":"2002","unstructured":"Sikaneta T, Williams WW, Chung RT, Cosimi AB, Pascual AM. Remission of hepatitis C virus-associated cryoglobulinemic glomerulonephritis with interferon alfa-2b and ribavirin combination therapy after liver transplantation. Transplantation. 2002;74(12):1767\u20138.","journal-title":"Transplantation"},{"issue":"2","key":"116_CR35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.mcg.0000225569.04773.8b","volume":"41","author":"M Montalbano","year":"2007","unstructured":"Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colledan M, Strazzabosco M. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver\/kidney transplant recipient. J Clin Gastroenterol. 2007;41(2):216\u201320.","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"116_CR36","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/QAD.0b013e32832ac36a","volume":"23","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Sene D, Cacoub P, et al. Kidney diseases in HIV\/HCV-co-infected patients. AIDS. 2009;23(10):1219\u201326.","journal-title":"AIDS"},{"issue":"14","key":"116_CR37","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1097\/QAD.0b013e32830e0152","volume":"22","author":"CM Wyatt","year":"2008","unstructured":"Wyatt CM, Malvestutto C, Coca SG, Klotman PE, Parikh CR. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS. 2008;22(14):1799\u2013807.","journal-title":"AIDS"},{"key":"116_CR38","first-page":"S1","volume":"109","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2008","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;109:S1\u201399.","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"116_CR39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","volume":"116","author":"F Dammacco","year":"2010","unstructured":"Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343\u201353.","journal-title":"Blood"},{"issue":"3","key":"116_CR40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","volume":"116","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha\/ribavirin compared with Peg-interferon-alpha\/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326\u201334.","journal-title":"Blood"},{"issue":"2","key":"116_CR41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","volume":"26","author":"CH Liu","year":"2011","unstructured":"Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol. 2011;26(2):228\u201339.","journal-title":"J Gastroenterol Hepatol"},{"key":"116_CR42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4254\/wjh.v7.i2.213","volume":"7","author":"C Bunchorntavakul","year":"2015","unstructured":"Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease. World J Hepatol. 2015;7:213\u201325.","journal-title":"World J Hepatol"},{"key":"116_CR43","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1086\/315355","volume":"181","author":"J Izopet","year":"2000","unstructured":"Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis. 2000;181:852\u20138.","journal-title":"J Infect Dis"},{"key":"116_CR44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/lt.500050417","volume":"5","author":"JK Delladetsima","year":"1999","unstructured":"Delladetsima JK, Boletis JN, Makris F, Psichogiou M, Kostakis A, Hatzakis A. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg. 1999;5:294\u2013300.","journal-title":"Liver Transpl Surg"},{"issue":"5","key":"116_CR45","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.V81.5.1132.1132","volume":"81","author":"C Ferri","year":"1993","unstructured":"Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood. 1993;81(5):1132\u20136.","journal-title":"Blood"},{"issue":"11","key":"116_CR46","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1056\/NEJM199403173301104","volume":"330","author":"R Misiani","year":"1994","unstructured":"Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330(11):751\u20136.","journal-title":"N Engl J Med"},{"issue":"4","key":"116_CR47","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/j.ajkd.2012.08.040","volume":"61","author":"F Fabrizi","year":"2013","unstructured":"Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61(4):623\u201337.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"116_CR48","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","volume":"54","author":"D Saadoun","year":"2006","unstructured":"Saadoun D, Resche-Rigon M, Thibault V, Piette J-C, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow up study. Arthritis Rheum. 2006;54(11):3696\u2013706.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"116_CR49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.23305","volume":"58","author":"D-A Landau","year":"2008","unstructured":"Landau D-A, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum. 2008;58(2):604\u201311.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"116_CR50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","volume":"62","author":"D Saadoun","year":"2015","unstructured":"Saadoun D, Resche Rigon M, Pol S, et al. Peg-IFN\u03b1Ribavirin\/Protease inhibitor combination in severe hepatitis C virus associated mixed cryoglobulinemia vasculitis. J Hepatol. 2015;62(1):24\u201330. doi: 10.1016\/j.jhep.2014.08.015 .","journal-title":"J Hepatol"},{"issue":"9","key":"116_CR51","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.dld.2014.05.017","volume":"46","author":"L Gragnani","year":"2014","unstructured":"Gragnani L, Fabbrizzi A, Triboli E, et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis. 2014;46(9):833\u20137.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"116_CR52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"European Association for Study of Liver","year":"2014","unstructured":"European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392\u2013420.","journal-title":"J Hepatol"},{"key":"116_CR53","doi-asserted-by":"crossref","first-page":"S640","DOI":"10.1016\/S0168-8278(15)31016-3","volume":"62","author":"D Saadoun","year":"2015","unstructured":"Saadoun D, Thibault V, Pialoux G, Elkrief L, Mallet M, Musset L, et el. All oral therapy (Sofosbuvir-Ribavirin) combination in severe HCV-mixed cryoglobulinemia vasculitis, The VASCULVADIC study. J Hepatol. 2015;62:S640.","journal-title":"J Hepatol"},{"key":"116_CR54","doi-asserted-by":"publisher","unstructured":"Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C Virus-associated mixed cryoglobulinemia with sofosbuvir-based direct-acting antiviral agents. Hepatology. 2016;63(2). doi: 10.1002\/hep.28297 .","DOI":"10.1002\/hep.28297"},{"issue":"12","key":"116_CR55","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1093\/ndt\/gfh469","volume":"19","author":"D Roccatello","year":"2004","unstructured":"Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transpl. 2004;19(12):3054\u201361.","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"116_CR56","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2007.081653","volume":"67","author":"D Saadoun","year":"2008","unstructured":"Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008;67(10):1431\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"116_CR57","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","volume":"101","author":"D Sansonno","year":"2003","unstructured":"Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101(10):3818\u201326.","journal-title":"Blood"},{"issue":"10","key":"116_CR58","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F Zaja","year":"2003","unstructured":"Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101(10):3827\u201334.","journal-title":"Blood"},{"issue":"3","key":"116_CR59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/ard.2006.065565","volume":"67","author":"P Cacoub","year":"2008","unstructured":"Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis. 2008;67(3):283\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"116_CR60","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","volume":"64","author":"S Vita De","year":"2012","unstructured":"De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843\u201353.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"116_CR61","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","volume":"64","author":"MC Sneller","year":"2012","unstructured":"Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835\u201342.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"116_CR62","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/acr.21990","volume":"65","author":"N Droz","year":"2013","unstructured":"Droz N, Gilardin L, Cacoub P, et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res. 2013;65(9):1504\u201314.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"116_CR63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood-2009-11-253948","volume":"116","author":"A Petrarca","year":"2010","unstructured":"Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010;116(3):335\u201342.","journal-title":"Blood"},{"issue":"4","key":"116_CR64","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/acr.21856","volume":"65","author":"D Saadoun","year":"2013","unstructured":"Saadoun D, Pineton de Chambrun M, Hermine O, et al. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res. 2013;65(4):643\u20137.","journal-title":"Arthritis Care Res"},{"key":"116_CR65","doi-asserted-by":"crossref","unstructured":"Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol. 2016. pii: ASN.2016010030.","DOI":"10.1681\/ASN.2016010030"},{"key":"116_CR66","doi-asserted-by":"crossref","first-page":"S784","DOI":"10.1016\/S0168-8278(16)01530-0","volume":"64","author":"KR Bhamidimarri","year":"2016","unstructured":"Bhamidimarri KR, Martin P, Levy P, et al. Renal function decline is frequent in patients underegoing hepatitis C treatment post kidney transplant. J Hepatol. 2016;64:S784.","journal-title":"J Hepatol."},{"issue":"7","key":"116_CR67","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros PJ, Reddy KR, \u00a0Mantry PS, Cohen E, Bennett M, et al. Efficacy of direct-acting antiviral combination for patients with HCV genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150(7):1590\u20138. doi: 10.1053\/j.gastro.2016.02.078 .","journal-title":"Gastroenterology"},{"issue":"10003","key":"116_CR68","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537\u201345.","journal-title":"Lancet"},{"issue":"suppl 4","key":"116_CR69","first-page":"1940","volume":"60","author":"WW Yeh","year":"2014","unstructured":"Yeh WW, Caro L, Guo Z, et al. Pharmacokinetics of co-administered HCV protease inhibitor MK-5172 and NS5A inhibitor MK-8742 in volunteers with end-stage renal disease on hemodialysis or severe renal impairment not on hemodialysis. Hepatology. 2014;60(suppl 4):1940.","journal-title":"Hepatology"},{"key":"116_CR70","unstructured":"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm483828.htm ."},{"key":"116_CR71","doi-asserted-by":"crossref","unstructured":"Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with impaired renal function. Liver Int. 2016.","DOI":"10.1111\/liv.13102"},{"issue":"6","key":"116_CR72","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/liv.13025","volume":"36","author":"HE Nazario","year":"2016","unstructured":"Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on hemodialysis or GFR <30\u00a0mL\/min. Liver Int. 2016;36(6):798\u2013801. doi: 10.1111\/liv.13025 .","journal-title":"Liver Int"},{"issue":"6","key":"116_CR73","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/liv.13078","volume":"36","author":"T Singh","year":"2016","unstructured":"Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir based treatment is safe and effective in patients with chronic hepatitis C infection and end-stage renal disease: a case series. Liver Int. 2016;36(6):802\u2013806. doi: 10.1111\/liv.13078 .","journal-title":"Liver Int"},{"key":"116_CR74","doi-asserted-by":"publisher","unstructured":"Maruyama A, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2015. doi: 10.1093\/ndt\/gfv361","DOI":"10.1093\/ndt\/gfv361"},{"issue":"7","key":"116_CR75","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","volume":"54","author":"BJ Kirby","year":"2015","unstructured":"Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54(7):677\u201390.","journal-title":"Clin Pharmacokinet"},{"key":"116_CR76","unstructured":"Martin P, Gane EJ, Ortiz-Lasanta G, et al. Safety and efficacy of treatment with daily sofosbuvir 400\u00a0mg\u00a0+\u00a0ribavirin 200\u00a0mg for 24 weeks in genotype 1 or 3 HCV-infected patients with severe renal impairment. Poster 1128, AASLD abstract Hepatology, vol 62, 1(suppl)."},{"issue":"3","key":"116_CR77","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27922","volume":"62","author":"V Saxena","year":"2015","unstructured":"Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir\/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62(3):715\u201325.","journal-title":"Hepatology."},{"key":"116_CR78","unstructured":"Janssen, Inc (simeprevir) product monography, 2015 and Simion A, Mortier S, Peeters M, et al. Pharmacokinetics of Simeprevir (TMC435) in volunteers with severe renal impairment. In: 8th HEPCam workshop\u2014clinical pharmacology, Cambridge, UK, 26\u201328 June 2013 http:\/\/regist2.virology-education.com\/2013\/8hepcam\/docs\/04_simion.pdf ."},{"key":"116_CR79","unstructured":"Ledipasvir\/Sofosbuvir (Harvoni\u00ae) National Drug Monograph. VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist Executives and Office of Public Health. 2014. https:\/\/vaww.cmopnational.va.gov\/cmop\/PBM\/default.aspx ."},{"issue":"5","key":"116_CR80","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP2941","volume":"20","author":"T Garimella","year":"2015","unstructured":"Garimella T, Wang R, Luo WL, et al. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Therapy. 2015;20(5):535\u201343.","journal-title":"Antivir Therapy"},{"key":"116_CR81","doi-asserted-by":"crossref","unstructured":"AbbVie Corp. Hlkira PAK ombitasvir\/paritaprevir\/ritonavir 12.5\/75\/50\u00a0mg and dasabuvir 250\u00a0mg, tablets product monograph, 2014.","DOI":"10.1310\/hpj5005-396"},{"key":"116_CR82","unstructured":"Khatri A, Dutta S, Marbury T, et al. The pharmacokinetics and safety of the direct acting antiviral regimen of ABT-450\/r, ombitasvir with\/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. In: 65th annual meeting of the American Association for the Study of Liver Diseases Boston, 2014."},{"key":"116_CR83","unstructured":"Pockros PJ, et al. Ombitasvir-paritaprevir-ritonavir and dasabuvir in GT1 & renal disease RUBY-I: 50th EASL. 2015; Abstract L01."},{"issue":"Suppl 4","key":"116_CR84","first-page":"1940","volume":"60","author":"W Yeh","year":"2014","unstructured":"Yeh W, Caro L, Guo Z, et al. Pharmacokinetics of co-administered HCV protease inhibitor Grazoprevir (MK-5172) and NS5A Elbasvir (MK-8742) in volunteers with end-stage renal disease on hemodialysis or severe renal impairment not on hemodialysis. J Hepatol. 2014;60 Suppl 4:1940.","journal-title":"J Hepatol"},{"issue":"10003","key":"116_CR85","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537\u201345.","journal-title":"Lancet."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-016-0116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T20:23:33Z","timestamp":1656793413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-016-0116-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["116"],"URL":"https:\/\/doi.org\/10.1007\/s40121-016-0116-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}